Fibreoptic-guided tracheal intubation using a supraglottic airway device as a conduit is a technique that can be used in anticipated and unanticipated difficult airway management. Although the i-gel â supraglottic airway device has been examined for this purpose, the LMA â Protector TM , a recently introduced secondgeneration supraglottic airway device, has not been evaluated for this use in clinical trials. This prospective, randomised clinical trial compared fibreoptic-guided tracheal intubation via i-gel and LMA Protector supraglottic airway devices in two UK hospitals. Patients who were ASA physical status 1 or 2 and undergoing elective surgery requiring tracheal intubation were recruited to the study. A block randomisation list was generated for each study site. The primary outcome measure was time to successful tracheal intubation and secondary outcomes were tracheal intubation success rate, glottic view through flexible fibrescope, ease of tracheal intubation using operator visual analogue score, supraglottic airway device insertion time and insertion success rate. Ninety patients were randomly allocated to each device, and final data analysis was carried out for 92 patients in the i-gel group and 86 patients in the LMA Protector group. Mean (SD) tracheal intubation time in the i-gel and LMA Protector groups were 54.3 (13.8) s and 52.0 (13.0) s, respectively (p = 0.240). There were no significant differences in tracheal intubation success rate, glottic view and ease of tracheal intubation between the two groups. This study demonstrates that the LMA Protector supraglottic airway device is comparable to the i-gel supraglottic airway device as a conduit for fibreoptic-guided tracheal intubation.
Introduction
Fibreoptic-guided tracheal intubation through a supraglottic airway device (SAD) is a technique described in 'Plan B' of the Difficult Airway Society (DAS) guidelines for features to minimise the risk of gastric aspiration and are recommended for use in routine clinical practice, as well as to rescue failed tracheal intubation [3] . The ability to perform tracheal intubation via a SAD can influence the type of SAD used when managing a difficult airway.
The i-gel â (Intersurgical, Berkshire, UK) is a secondgeneration SAD used in both anaesthesia and resuscitation.
Fibreoptic-guided tracheal intubation via the i-gel SAD has been shown to have a high first-attempt success rate [4, 5] and provide a favourable glottic view [6] .
The LMAâ Protector TM (Teleflex Medical airway seal [7] [8] [9] . In addition, the airway lumen of the LMA Protector is wide enough to pass an adequately sized tracheal tube. Hence, using the LMA Protector as a conduit for fibreoptic-guided tracheal intubation should be easy [10] . The precursor to the LMA Protector, the LMAâ ProSeal TM (Teleflex Medical) , was found to be comparable to the LMAâ Classic TM (Teleflex Medical) , as a conduit for fibreoptic-guided tracheal intubation [11] . However, there is no previous randomised trial primarily comparing fibreoptic-guided tracheal intubation via the LMA Protector with an established SAD.
The aim of this study was to compare fibreoptic-guided tracheal intubation through the i-gel with the LMA Protector using tracheal intubation time as the primary outcome.
Methods
The study was approved by a research ethics committee. On arrival in the anaesthetic room, standard monitoring [12] was instituted. It was ensured that both SADs and a flexible fibrescope were available and ready to use for each study patient. After completion of the pre-surgical checklist, immediately before pre-oxygenation, group allocation was revealed. It was not possible to blind the investigators or other healthcare professionals to the group allocation.
All patients received pre-oxygenation to achieve a fractional end-tidal oxygen concentration ≥ 0.80. General anaesthesia was induced with fentanyl or remifentanil and propofol followed by neuromuscular blockade using either atracurium or rocuronium. An age-adjusted end-tidal volatile concentration of 1 minimum alveolar concentration (MAC) was achieved and maintained throughout the procedure.
Following the absence of all twitches to train-of-four stimulation of the ulnar nerve, the SAD was inserted. We used the manufacturer's recommendations in choosing the size of the relevant SAD. For the LMA Protector, we followed the insertion technique recommended by the manufacturer [13] , where the device is slid along the hard palate using a slightly diagonal approach with the tip facing away from the midline. It is then rotated in a circular motion to follow the contours of the mouth and inserted until resistance is felt at the upper oesophageal sphincter. After insertion, the cuff of the device was inflated with sufficient air to prevent an air leak with positive-pressure ventilation. The i-gel was placed using a standard midline insertion technique and inserted along the hard palate and advanced until resistance was felt.
During the procedure, we recorded the SAD insertion The sample size was calculated based on the primary outcome measure of time to successful tracheal intubation.
We could not find similar studies using the LMA Protector to determine an appropriate standard deviation to use.
Therefore, we used a standardised effect size. To observe a standardised difference of 0.5, which corresponds to a moderate difference, we required 85 patients (170 in total)
for a study with 90% power. To account for failure and exclusions, we decided to recruit 180 patients in total. Time to view carina, tracheal intubation time, SAD insertion time and operator VAS for fibreoptic-guided tracheal intubation were analysed using Student's t-test after examination using Levene's test for equality of variance. Grade of glottic view, SAD insertion attempts, and incidence of tracheal tube impingement were analysed using Chi-squared test. Ease of SAD insertion scores were analysed using Mann-Whitney U-test. Statistical significance was taken as p < 0.05.
Analysis was carried out using R statistical software (R Foundation for Statistical Computing, Vienna, Austria).
Results
In total, 180 patients were randomly allocated to two study groups (Fig. 2) . Final analysis was based on the total number of fibreoptic tracheal intubations performed through each SAD. Baseline characteristics and airway assessment data were similar between the two groups (Table 1 ). There were no significant differences in tracheal intubation time, time to view carina, success rate, glottic view and ease of tracheal intubation between the two groups ( Table 2) . However, there were statistically significant differences in the incidence of tube impingement (Table 2) , SAD insertion time, ease of SAD insertion and the number of SAD insertion attempts (Table 3 ).
In the LMA Protector group, SAD insertion failed in two patients; following two attempts at insertion, it was not possible to achieve adequate tidal volumes. An i-gel was successfully inserted and following confirmation of correct placement, fibreoptic-guided tracheal intubation was performed through the i-gel in both patients. In one patient allocated to the LMA Protector group, insertion of both devices failed (two attempts at LMA Protector and one attempt with i-gel failed to achieve adequate ventilation).
Therefore, tracheal intubation was performed using direct laryngoscopy. In another patient allocated to the LMA Protector group, fibreoptic-guided tracheal intubation was 
Discussion
The primary aim of this study was to compare fibreoptic-guided tracheal intubation via two second- The success rate of fibreoptic-guided tracheal intubation through the i-gel varies from 91% to 100% [4, 5, 18] , which is similar to our study. The findings of our study support the use of the LMA Protector as an alternative SAD in this regard. However, in contrast to these findings, our study found significant differences between the two devices with regard to their success and ease of initial placement. was more difficult to insert, with a higher incidence of second-or third-attempt insertions [23] . They hypothesised that the difficulty in insertion could be due to the softer component material (silicone) of the LMA Protector which could increase the chance of kinking of the mask tip and malpositioning. The ease of use of the i-gel in our study is comparable with other studies [4, 6, 18, [25] [26] [27] [28] [29] . An overall a In two patients randomly allocated to the LMA Protector group, due to failed insertion of the LMA Protector, the i-gel was used instead. b Two patients randomly allocated to the LMA Protector group underwent direct laryngoscopy and tracheal intubation (one due to failed insertion of both devices and one due to failed fibreoptic-guided tracheal intubation).
2% failure rate of insertion and ventilation via SADs has been described [30] .
This study has several strengths. It is a two-centre study, adequately powered to assess the primary outcome with groups that were well-matched at baseline. The study findings are immediately applicable to clinical practice, in particular that fibreoptic-guided tracheal intubation via the LMA Protector device compares well to the established i-gel SAD. However, there are certain limitations to our study.
Although differences were found in this study regarding SAD insertion time and insertion success rate, this study was not adequately powered for these end-points. We did not a In two patients randomly allocated to the LMA Protector group, due to failed insertion of the LMA Protector, the i-gel was used instead. b Two patients randomly allocated to the LMA Protector group underwent direct laryngoscopy and tracheal intubation (one due to failed insertion of both devices and one due to failed fibreoptic-guided tracheal intubation). a In two patients randomly allocated to the LMA Protector group, due to failed insertion of the LMA Protector, the i-gel was used instead. b Two patients randomised to the LMA Protector group underwent direct laryngoscopy and tracheal intubation (one due to failed insertion of both devices and one due to failed fibreoptic-guided tracheal intubation).
study other clinical end-points such as incidence of sore throat, desaturation, airway trauma and patient satisfaction.
We also did not study patients with BMI > 40 kg.m À2 or those with a predicted difficult airway. This limits our ability to draw conclusions on the performance of the devices as part of a tracheal intubation technique in these patient groups, which can be encountered as part of routine anaesthetic practice. However, this study can reassure anaesthetists to a degree regarding its potential use in these situations.
In conclusion, our study demonstrates that the LMA Protector functions similarly well as a conduit for fibreopticguided tracheal intubation in comparison with the i-gel.
Further randomised trials comparing the insertion characteristics of these two devices would be useful in supporting the choice of SAD, particularly as a rescue device in difficult airway management.
